Malignant serous fluid: Cat 5
- A recent cytology post showed high‑grade serous carcinoma diagnosed in pleural fluid and reported as 'Category 5.' (x.com) - The case discussion explicitly used the International System for Reporting Serous Fluid Cytology to categorize it as malignant. (x.com) - The poster noted that a Category 5 fluid result has direct implications for staging and urgent oncology referral. (x.com)
Doctors use fluid cytology the way mechanics use an oil sample: they look for cells floating in a body cavity to find the source of a problem. In pleural fluid around the lung, a Category 5 result means malignant cells are present, not just suspicious ones. (pmc.ncbi.nlm.nih.gov) That Category 5 label comes from the International System for Reporting Serous Fluid Cytopathology, a five-step reporting scheme published in 2020 by the International Academy of Cytology and the American Society of Cytopathology. The system sorts samples into nondiagnostic, negative for malignancy, atypia of undetermined significance, suspicious for malignancy, and malignant. (xiahepublishing.com) In a 2,318-patient institutional series published in 2023, 489 effusion samples were classified as malignant, and the risk of malignancy for that category was 96.5%. The same study included 1,614 pleural fluid samples, showing how often the pleural space is part of routine cytology work. (pmc.ncbi.nlm.nih.gov) High-grade serous carcinoma is the most common histologic subtype in ovarian, fallopian tube, and primary peritoneal cancer. The National Cancer Institute says these tumors are now staged and treated similarly because they share a common Müllerian origin and similar management. (cancer.gov) When high-grade serous carcinoma shows up in pleural fluid, the finding can change stage, not just wording on a report. The 2014 FIGO staging system classifies pleural effusion with positive cytology as stage IVA disease for ovarian, fallopian tube, and primary peritoneal cancer. (pmc.ncbi.nlm.nih.gov) That is why pathologists push for a standardized label instead of a vague description. The reporting system was designed to improve reproducibility between labs and give clinicians a clearer link between a cytology result, cancer risk, and next-step management. (xiahepublishing.com) Pleural involvement is not the usual first clue in gynecologic cancer. A 2024 case report described a 53-year-old woman whose first major finding was a massive right pleural effusion, with pleural fluid cytology and immunostains confirming high-grade serous carcinoma of ovarian origin. (pmc.ncbi.nlm.nih.gov) That patient’s imaging showed no ascites, no peritoneal carcinomatosis, and no ovarian mass at presentation, which is why the fluid diagnosis mattered so much. She was treated with carboplatin and paclitaxel, plus palliative management for recurrent effusion. (pmc.ncbi.nlm.nih.gov) So a “Cat 5” pleural fluid result is not shorthand for “keep watching.” In this system, it is the reportable point where malignant cells in fluid can lock in a diagnosis, support staging, and speed referral to oncology. (pmc.ncbi.nlm.nih.gov)
